Elamipretide丨CAS 736992-21-5

Elamipretide is a mitochondria-targeted peptide under investigation for therapeutic applications related to mitochondrial dysfunction. It is primarily studied in the treatment of rare mitochondrial diseases, cardiomyopathies, and neurodegenerative disorders, where impaired mitochondrial function leads to cellular energy deficits and oxidative stress. In clinical research, Elamipretide is used to explore cardioprotective, neuroprotective, and metabolic effects, often in conditions such as heart failure, Leber's hereditary optic neuropathy, and primary mitochondrial myopathies. Its unique mechanism enables it to interact with cardiolipin in the inner mitochondrial membrane, stabilizing mitochondrial structure and improving ATP production. Elamipretide is also employed in preclinical studies to investigate oxidative stress modulation, mitochondrial respiration, and tissue energy metabolism.

Elamipretide offers several advantages due to its targeted mitochondrial action and peptide-based design. By selectively localizing to mitochondria, it helps restore mitochondrial function, reduce reactive oxygen species (ROS) production, and improve cellular energy efficiency. The peptide's mechanism supports tissue protection under stress conditions, including ischemia-reperfusion injury and metabolic dysfunction. It demonstrates favorable pharmacological properties, including specificity for mitochondrial membranes and a low risk of off-target effects. Additionally, Elamipretide has been shown to improve organ function and endurance in preclinical models, highlighting its therapeutic potential for conditions associated with mitochondrial impairment.